Article info
PDFCommentary: General medicine
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate
- Correspondence to Dr Graziella Filippini, Scientific Director’s Office, Carlo Besta Foundation and Neurological Institute, Milan 20133, Italy; graziella.filippini{at}istituto-besta.it
Citation
Ocrelizumab appears to reduce relapse and disability in multiple sclerosis but quality of evidence is moderate
Publication history
- Accepted August 27, 2017
- First published November 8, 2017.
Online issue publication
March 03, 2018
Article Versions
- Previous version (2 March 2018).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.